Follow Health Care Reform Insider on Twitter
Loading...
You are here:  Home  >  Opinion  >  Editorials  >  Current Article

Biosimilar approval is long overdue

November 13, 2014 

Generic versions of brand-name chemically based drugs are well-established in the U.S. market. However, even though the Food and Drug Administration (FDA) was given the authority in 2010 to create a pathway to approve a “generic” version of a biologic drug, more properly called a “biosimilar,” the agency has not approved a single one.

http://thehill.com/blogs/pundits-blog/healthcare/223583-biosimilar-approval-is-long-overdue

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>